With over 30+ players proactively involved in developing novel therapies for Non-Muscle Invasive Bladder Cancer (NMIBC) and over 30+ therapies expected to get launched, Non-Muscle Invasive Bladder Cancer Pipeline presents quite a promising overall picture for the next decade.
“Non-Muscle Invasive Bladder Cancer (NMIBC) Pipeline Insight, 2022” by DelveInsight highlights the details around the NMIBC pipeline scenario, unmet needs, and Non-Muscle Invasive Bladder Cancer therapeutic assessment of the key pipeline therapies.
Some of the key Non-Muscle Invasive Bladder Cancer Pipeline Highlights:
Non-Muscle Invasive Bladder Cancer is a common, heterogeneous cancer found in the tissue of the bladder’s inner surface, wherein the bladder muscle is not involved.
NMIBC Pipeline Therapies
Opdivo: Bristol-Myers Squibb/Ono Pharmaceuticals
Opdivo (Nivolumab) is a programmed death-1 (PD-1) immune checkpoint inhibitor developed by Bristol-Myers Squibb. The drug harnesses the body’s immune system to help restore anti-tumor immune response by blocking the interaction between PD-1 and its ligands.
Opdivo holds a vital place as the treatment option across multiple cancers. It has been approved for colorectal cancer; gastric cancer; Head and neck cancer; Hodgkin’s disease; Liver cancer; Malignant melanoma; Mesothelioma; Non-small cell lung cancer; Renal cell carcinoma; Urogenital cancer, and is currently in phase III clinical development for participants with High-risk Non-muscle Invasive Bladder Cancer that is persistent or recurrent after treatment with BCG in a phase III trial titled “a phase III, randomized, double-blind trial of Nivolumab in combination with Intravesical BCG Versus Standard of Care BCG alone’’ (NCT04149574). The trial is currently in the recruiting stage with an estimated enrollment of 700 participants and expected to be completed in August 2030.
BMS is also evaluating Opdivo in a phase II trial titled “a phase II, randomized, open-label study of Nivolumab or Nivolumab/BMS-986205 alone or combined with intravesical BCG in participants with BCG-Unresponsive, high-risk, Non-Muscle Invasive Bladder Cancer” (NCT03519256). The trial is currently in the recruiting stage with an estimated enrollment of 358 participants and expected to be completed in September 2024.
UGN-102: UroGen Pharma
UGN-102 (mitomycin gel) is an investigational formulation that utilizes innovative technology, RTGel reverse-thermal hydrogel, for the treatment of low-grade NMIBC.
UroGen Pharma is investigating the therapy in phase 3, to assess the long-term efficacy and safety of UGN-102 (mitomycin) for an intravesical solution with or without (±) transurethral resection of bladder tumors. The trial is currently in the recruiting stage with an estimated enrolment of 632 participants and expected to be completed in December 2023.
Atezolizumab: Hoffmann-La Roche
Roche’s Atezolizumab (Tecentriq), a monoclonal antibody designed to bind with a protein called PD-L1 expressed on tumour cells and tumour-infiltrating immune cells, is already commercially available for Breast cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Small cell lung cancer; and Urogenital cancer. Roche is also evaluating the drug for Non-Muscle Invasive Bladder Cancer. It is currently in the recruiting stage with an estimated enrollment of 614 participants and expected to be completed in February 2028.
To learn more about NMIBC Drugs Development, request NMIBC Drugs Pipeline Sample Report
Scope of NMIBC Pipeline Report
Coverage: Global
Major Players: 30+ companies
Prominent Players: Bristol-Myers Squibb, Ono Pharmaceuticals, Pfizer, Merck Sharp & Dohme Corp., Ferring Pharmaceuticals, UroGen Pharma, Roche, Viventia Bio, ImmunityBio
Key Drugs: 30+ pipeline drugs
Non-Muscle Invasive Bladder Cancer Therapies: Atezolizumab, ALT-803, UGN-102, Vicinium, Nivolumab, Pembrolizumab, PF-06801591, Durvalumab, APL-1202
Phases
Targets
Mechanism of Action
Molecule Types
Route of Administration
Product Types
Visit to know more about the report offerings @ Non-Muscle Invasive Bladder Cancer Emerging Therapies
Key Questions Answered in Non-Muscle Invasive Bladder Cancer Pipeline Report
Get in touch with our Business Executive @ NMIBC Pipeline Trends and Futuristic Outlook to learn more about the domain.
Table of Contents
1
Introduction
2
Executive Summary
3
Non-Muscle Invasive Bladder Cancer: Overview
4
NMIBC Pipeline Therapeutics
5
Therapeutic Assessment
6
Non-Muscle Invasive Bladder Cancer – DelveInsight’s Analytical Perspective
7
In-depth Commercial Assessment
8
Non-Muscle Invasive Bladder Cancer Collaboration Deals
9
NMIBC Late-Stage Products
10
NMIBC Mid-Stage Products
11
NMIBC Early-Stage Products
12
NMIBC Pre-clinical and Discovery Stage Products
13
NMIBC Inactive Products
14
Non-Muscle Invasive Bladder Cancer Key Companies
15
Non-Muscle Invasive Bladder Cancer Key Products
16
NMIBC Unmet Needs
17
NMIBC Future Perspectives and Conclusion
18
Analyst Views on NMIBC Future Trends
19
Appendix
20
About DelveInsight
Other Trending Healthcare Reports by DelveInsight
22q11.2 Deletion Syndrome Market
“22q11.2 Deletion Syndrome Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the 22q11.2 Deletion Syndrome Market size, share, and trends in the 7MM. Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the 22q11.2 Deletion Syndrome therapeutics Market.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/non-muscle-invasive-bladder-cancer-pipeline-insight